LIVALO (pitavastatin)
Dyslipidemia
Key Facts
About Kowa Pharmaceuticals
Kowa Pharmaceuticals America is the U.S. subsidiary of the privately held, multinational Kowa Company, Ltd., established in 2008 to lead the development and commercialization of Kowa's pharmaceutical products in the American market. The company leverages its parent's long history of R&D, particularly in cardiovascular and metabolic diseases, and is anchored by its flagship statin, LIVALO (pitavastatin). It operates through three main U.S. entities: Kowa Pharmaceuticals America (commercialization), Kowa Research Institute (clinical development), and Kowa Science Institute (early discovery). With a strong emphasis on compliance, training, and collaborative partnerships, the company aims to deliver effective treatments and enhance the value of its pharmaceutical portfolio.
View full company profileTherapeutic Areas
Other Dyslipidemia Drugs
| Drug | Company | Phase |
|---|---|---|
| PRD004 | PRD Therapeutics | Discovery |